title: Protection of macaques against infection with simian type D retrovirus (SRV-1) by immunization with recombinant vaccinia virus expressing the envelope glycoproteins of either SRV-1 or Mason-Pfizer monkey virus (SRV-3).
abstract: Rhesus macaques were immunized with live vaccinia virus recombinants expressing the envelope glycoproteins (gp70 and gp22) of simian type D retrovirus (SRV), serotype 1 or 3. All of the animals immunized with either the SRV-1 env or the SRV-3 env vaccinia virus recombinant developed neutralizing antibodies against the homologous SRV. In addition, both groups developed cross-reactive antibodies and were protected against an intravenous live-virus challenge with SRV-1. The four control animals immunized with a vaccinia virus recombinant expressing the G protein of respiratory syncytial virus were not protected against the same SRV-1 challenge. Although SRV-1 and SRV-3 immune sera showed cross-neutralization, they failed to neutralize a separate, more distantly related serotype, SRV-2, in an in vitro assay. These findings are consistent with the known degree of serologic and genetic relatedness of these three SRV strains.
authors.affiliation: Department of Microbiology, University of Alabama, Birmingham 35294.
authors.forename: B A
authors.initials: BA
authors.lastname: Brody
authors.forename: E
authors.initials: E
authors.lastname: Hunter
authors.forename: J D
authors.initials: JD
authors.lastname: Kluge
authors.forename: R
authors.initials: R
authors.lastname: Lasarow
authors.forename: M
authors.initials: M
authors.lastname: Gardner
authors.forename: P A
authors.initials: PA
authors.lastname: Marx
mesh_terms: D000818:Animals; D000917:Antibody Formation; D000956:Antigens, Viral / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology; D015707:HN Protein; D016233:Immunotherapy, Active; D008251:Macaca; D012136:Respiratory Syncytial Viruses / Q000276:immunology; D015301:Retroviruses, Simian / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000628:therapy*; D013047:Specific Pathogen-Free Organisms; D014614:Vaccines, Synthetic / Q000627:therapeutic use*; D014616:Vaccinia virus / Q000235:genetics; D014759:Viral Envelope Proteins / Q000276:immunology; D014764:Viral Proteins
chemical_list: D000956:Antigens, Viral; D006023:Glycoproteins; D015707:HN Protein; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C116204:attachment protein G